Let's Make a Deal--Part II

I just wanted to note, as reinforcement of the previous post, that both of these deal were all cash.  Sanofi-Aventis coughed up $1.9 billion and Bucyrus antred $1.3 billion.  It's often instructive to note whether the currency being used is company stock (which may indicate that stocks are richly valued) or plain cold cash (a reliable indicator of stock bargains).  The fact that it is cash being thrown around is definitely a positive.